These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 17645871)

  • 1. Plasma PCSK9 levels correlate with cholesterol in men but not in women.
    Mayne J; Raymond A; Chaplin A; Cousins M; Kaefer N; Gyamera-Acheampong C; Seidah NG; Mbikay M; Chrétien M; Ooi TC
    Biochem Biophys Res Commun; 2007 Sep; 361(2):451-6. PubMed ID: 17645871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
    Cameron J; Bogsrud MP; Tveten K; Strøm TB; Holven K; Berge KE; Leren TP
    Transl Res; 2012 Aug; 160(2):125-30. PubMed ID: 22683370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma PCSK9 in nephrotic syndrome and in peritoneal dialysis: a cross-sectional study.
    Jin K; Park BS; Kim YW; Vaziri ND
    Am J Kidney Dis; 2014 Apr; 63(4):584-9. PubMed ID: 24315769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ABO blood group in relation to plasma lipids and proprotein convertase subtilisin/kexin type 9.
    Li S; Xu RX; Guo YL; Zhang Y; Zhu CG; Sun J; Li JJ
    Nutr Metab Cardiovasc Dis; 2015 Apr; 25(4):411-7. PubMed ID: 25466598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of PCSK9 polymorphisms on plasma lipids and response to atorvastatin treatment in Brazilian subjects.
    Anderson JM; Cerda A; Hirata MH; Rodrigues AC; Dorea EL; Bernik MM; Bertolami MC; Faludi AA; Hirata RD
    J Clin Lipidol; 2014; 8(3):256-64. PubMed ID: 24793346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma lipoprotein-associated phospholipase A2 is inversely correlated with proprotein convertase subtilisin-kexin type 9.
    Constantinides A; Kappelle PJ; Lambert G; Dullaart RP
    Arch Med Res; 2012 Jan; 43(1):11-4. PubMed ID: 22300679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PCSK9 gene mutations and low-density lipoprotein cholesterol.
    Wu NQ; Li JJ
    Clin Chim Acta; 2014 Apr; 431():148-53. PubMed ID: 24518357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Of PCSK9, cholesterol homeostasis and parasitic infections: possible survival benefits of loss-of-function PCSK9 genetic polymorphisms.
    Mbikay M; Mayne J; Seidah NG; Chrétien M
    Med Hypotheses; 2007; 69(5):1010-7. PubMed ID: 17502126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma PCSK9 levels are significantly modified by statins and fibrates in humans.
    Mayne J; Dewpura T; Raymond A; Cousins M; Chaplin A; Lahey KA; Lahaye SA; Mbikay M; Ooi TC; Chrétien M
    Lipids Health Dis; 2008 Jun; 7():22. PubMed ID: 18547436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol.
    Alborn WE; Cao G; Careskey HE; Qian YW; Subramaniam DR; Davies J; Conner EM; Konrad RJ
    Clin Chem; 2007 Oct; 53(10):1814-9. PubMed ID: 17702855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia.
    Cariou B; Ouguerram K; Zaïr Y; Guerois R; Langhi C; Kourimate S; Benoit I; Le May C; Gayet C; Belabbas K; Dufernez F; Chétiveaux M; Tarugi P; Krempf M; Benlian P; Costet P
    Arterioscler Thromb Vasc Biol; 2009 Dec; 29(12):2191-7. PubMed ID: 19762784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel loss-of-function PCSK9 variant is associated with low plasma LDL cholesterol in a French-Canadian family and with impaired processing and secretion in cell culture.
    Mayne J; Dewpura T; Raymond A; Bernier L; Cousins M; Ooi TC; Davignon J; Seidah NG; Mbikay M; Chrétien M
    Clin Chem; 2011 Oct; 57(10):1415-23. PubMed ID: 21813713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peptide-based anti-PCSK9 vaccines - an approach for long-term LDLc management.
    Galabova G; Brunner S; Winsauer G; Juno C; Wanko B; Mairhofer A; Lührs P; Schneeberger A; von Bonin A; Mattner F; Schmidt W; Staffler G
    PLoS One; 2014; 9(12):e114469. PubMed ID: 25474576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PCSK9 and LDL cholesterol: unravelling the target to design the bullet.
    Costet P; Krempf M; Cariou B
    Trends Biochem Sci; 2008 Sep; 33(9):426-34. PubMed ID: 18672372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secreted proprotein convertase subtilisin/kexin type 9 reduces both hepatic and extrahepatic low-density lipoprotein receptors in vivo.
    Schmidt RJ; Beyer TP; Bensch WR; Qian YW; Lin A; Kowala M; Alborn WE; Konrad RJ; Cao G
    Biochem Biophys Res Commun; 2008 Jun; 370(4):634-40. PubMed ID: 18406350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential effects of PCSK9 loss of function variants on serum lipid and PCSK9 levels in Caucasian and African Canadian populations.
    Mayne J; Ooi TC; Raymond A; Cousins M; Bernier L; Dewpura T; Sirois F; Mbikay M; Davignon J; Chrétien M
    Lipids Health Dis; 2013 May; 12():70. PubMed ID: 23663650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol.
    Kotowski IK; Pertsemlidis A; Luke A; Cooper RS; Vega GL; Cohen JC; Hobbs HH
    Am J Hum Genet; 2006 Mar; 78(3):410-22. PubMed ID: 16465619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The apoB-to-PCSK9 ratio: A new index for metabolic risk in humans.
    Wassef H; Bissonnette S; Saint-Pierre N; Lamantia V; Cyr Y; Chrétien M; Faraj M
    J Clin Lipidol; 2015; 9(5):664-75. PubMed ID: 26350813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relation of plasma PCSK9 levels to lipoprotein subfractions in patients with stable coronary artery disease.
    Xu RX; Li S; Zhang Y; Li XL; Guo YL; Zhu CG; Li JJ
    Lipids Health Dis; 2014 Dec; 13():188. PubMed ID: 25496400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of association between plasma PCSK9 and LDL-apoB100 catabolism in patients with uncontrolled type 2 diabetes.
    Vergès B; Duvillard L; Brindisi MC; Gautier E; Krempf M; Costet P; Cariou B
    Atherosclerosis; 2011 Nov; 219(1):342-8. PubMed ID: 21889145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.